DK2034999T3 - DHA-estere og anvendelse deraf i behandlingen og forebyggelsen af cardiovaskulære sygdomme - Google Patents

DHA-estere og anvendelse deraf i behandlingen og forebyggelsen af cardiovaskulære sygdomme

Info

Publication number: DK2034999T3
Authority: DK; Denmark
Prior art keywords: prevention; treatment; cardiovascular diseases; dha esters; dha
Prior art date: 2006-06-23

Application number

DK07765584.3T

Other languages

English (en)

Inventor

Andre Delhon

Jean Gardette

Jean Francois Patoiseau

Alain Marty

Frederique Brune

Etienne Severac

Original Assignee

Pf Medicament

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-23

Filing date

2007-06-22

Publication date

2011-01-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37686083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2034999(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-06-22 Application filed by Pf Medicament filed Critical Pf Medicament

2011-01-24 Application granted granted Critical

2011-01-24 Publication of DK2034999T3 publication Critical patent/DK2034999T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/02—Preparation of carboxylic acid esters by interreacting ester groups, i.e. transesterification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Cardiology (AREA)
Public Health (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pyridine Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK07765584.3T 2006-06-23 2007-06-22 DHA-estere og anvendelse deraf i behandlingen og forebyggelsen af cardiovaskulære sygdomme DK2034999T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0605649A FR2902659A1 (fr)	2006-06-23	2006-06-23	Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
PCT/EP2007/056277 WO2007147899A2 (en)	2006-06-23	2007-06-22	Dha esters and use thereof in treatment and prevention of cardiovascular disease

Publications (1)

Publication Number	Publication Date
DK2034999T3 true DK2034999T3 (da)	2011-01-24

Family

ID=37686083

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK07765584.3T DK2034999T3 (da)	2006-06-23	2007-06-22	DHA-estere og anvendelse deraf i behandlingen og forebyggelsen af cardiovaskulære sygdomme

Country Status (38)

Country	Link
US (2)	US8034377B2 (da)
EP (1)	EP2034999B9 (da)
JP (1)	JP5053372B2 (da)
KR (1)	KR101380128B1 (da)
CN (1)	CN101472590A (da)
AR (1)	AR061622A1 (da)
AT (1)	ATE489091T1 (da)
AU (1)	AU2007262958B2 (da)
BR (1)	BRPI0713725A2 (da)
CA (1)	CA2655570C (da)
CL (1)	CL2010001123A1 (da)
CO (1)	CO6150156A2 (da)
CR (1)	CR10507A (da)
DE (1)	DE602007010776D1 (da)
DK (1)	DK2034999T3 (da)
EC (1)	ECSP099039A (da)
ES (1)	ES2355611T3 (da)
FR (1)	FR2902659A1 (da)
GE (1)	GEP20125464B (da)
HN (1)	HN2008001771A (da)
HR (1)	HRP20110086T1 (da)
IL (1)	IL195562A (da)
MA (1)	MA30584B1 (da)
MX (1)	MX2009000103A (da)
MY (1)	MY145985A (da)
NO (1)	NO20090334L (da)
NZ (1)	NZ573454A (da)
PL (1)	PL2034999T3 (da)
PT (1)	PT2034999E (da)
RS (1)	RS51629B (da)
RU (1)	RU2451672C2 (da)
SA (1)	SA07280345B1 (da)
SI (1)	SI2034999T1 (da)
TN (1)	TNSN08527A1 (da)
TW (1)	TWI389888B (da)
UA (1)	UA96156C2 (da)
WO (1)	WO2007147899A2 (da)
ZA (1)	ZA200900334B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2334536B1 (es) *	2008-04-11	2011-01-24	Universidad Complutense De Madrid	Procedimiento para la obtencion selectiva de 12-hidroxi-9-cis-octadecenoato de (1,4:3,6-dianhidro-d-glucitol) utilizando lipasas inmovilizadas como catalizador.
FR2949063B1 (fr) *	2009-08-11	2011-09-30	Pf Medicament	Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
KR20180086297A (ko) *	2010-06-18	2018-07-30	엑스바이오테크, 인크.	관절염 치료
FR2963790B1 (fr) *	2010-08-11	2012-09-28	Pf Medicament	Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
CN103153340A (zh)	2010-08-23	2013-06-12	埃克斯生物科技公司	对肿瘤疾病的治疗
US9724409B2 (en)	2011-04-01	2017-08-08	Xbiotech, Inc.	Treatment of inflammatory skin disease
CN102757444B (zh) *	2011-04-29	2016-02-10	南京信诺泰医药有限公司	具有一氧化氮供体性质的苯并呋喃类化合物
FR2998479B1 (fr) *	2012-11-27	2017-04-28	Pf Medicament	Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
WO2016024283A1 (en) *	2014-08-12	2016-02-18	Praj Industries Limited	Process for the preparation of triglycerides of epa and dha
US10441087B2 (en)	2015-02-24	2019-10-15	Sleep Number Corporation	Mattress with adjustable firmness
KR20190117579A (ko)	2017-02-16	2019-10-16	엑스바이오테크, 인크.	화농성 한선염의 치료
JP2020508308A (ja) *	2017-02-20	2020-03-19	ボードオブスーパーバイザーズオブルイジアナステートユニバーシティアンドアグリカルチュアルアンドメカニカルカレッジ	心房細動の治療及び予防における硫化水素及び／又は亜硝酸塩
CN110950881A (zh) *	2018-09-27	2020-04-03	中国科学院上海药物研究所	一类三环类似物、其制备方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL133049C (da)	1966-02-24
JPS5967263A (ja)	1982-10-07	1984-04-16	Terumo Corp	ペンタエン高級脂肪酸ピリジルアルコ−ルエステルおよびその製法
JPS5967264A (ja)	1982-10-08	1984-04-16	Terumo Corp	血小板凝集抑制剤
EP0125252A1 (de) *	1982-11-16	1984-11-21	MOTSCHAN, Georges	Neue verwendung eines einzelnen vitamins oder einer kombination verschiedener vitamine
JPS6034947A (ja) *	1983-08-05	1985-02-22	Terumo Corp	ドコサヘキサエン酸誘導体およびそれを用いた血小板凝集阻止剤
GB9300125D0 (en) *	1993-01-06	1993-03-03	Scotia Holdings Plc	Compositions containing esters of unsaturated fatty acids
US5760081A (en) *	1994-05-10	1998-06-02	The General Hospital Corporation	Omega 3 fatty acids in the prevention of ventricular fibrillation
NZ306510A (en)	1995-05-01	1999-05-28	Scotia Holdings Plc	Niacin derivatives which include a fatty acid or fatty acid alcohol residue and their use in medicaments and skin care compositions
IL118092A0 (en)	1995-05-03	1996-09-12	Smithkline Beecham Plc	Antibacterial compounds their preparation and pharmaceutical compositions containing them
US5795909A (en)	1996-05-22	1998-08-18	Neuromedica, Inc.	DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) *	1996-05-22	1999-07-06	Neuromedica, Inc.	Taxane compounds and compositions
AUPQ480399A0 (en)	1999-12-22	2000-02-03	Commonwealth Scientific And Industrial Research Organisation	Unsaturated fatty acids and their uses in therapy
DK1157692T3 (da)	2000-05-22	2006-02-06	Pro Aparts Investimentos E Con	Sammensætning af fedtsyrer indeholdende mindst 80 vægt-% EPA og DHA, derivater deraf og farmaceutisk anvendelse deraf
ITMI20010129A1 (it) *	2001-01-25	2002-07-25	Pharmacia & Upjohn Spa	Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
US7704542B2 (en) *	2001-09-12	2010-04-27	Xanodyne Pharmaceuticals, Inc.	Vitamin/mineral compositions with DHA
US8729124B2 (en) *	2002-03-05	2014-05-20	Pronova Biopharma Norge As	Use of EPA and DHA in secondary prevention
ITMI20022511A1 (it) *	2002-11-26	2004-05-27	Victorix Assets Ltd	Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
WO2004091603A1 (fr) *	2003-04-07	2004-10-28	Clinigenetics	Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires
EP1466597A1 (en) *	2003-04-07	2004-10-13	Clinigenetics	Use of dha esters to control or prevent cardiovascular diseases
RU2005135565A (ru)	2003-04-17	2006-07-27	БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE)	Поливитаминная и минеральная добавка для беременных женщин

2006
- 2006-06-23 FR FR0605649A patent/FR2902659A1/fr active Pending
2007
- 2007-06-22 MX MX2009000103A patent/MX2009000103A/es active IP Right Grant
- 2007-06-22 AT AT07765584T patent/ATE489091T1/de active
- 2007-06-22 SI SI200730469T patent/SI2034999T1/sl unknown
- 2007-06-22 PT PT07765584T patent/PT2034999E/pt unknown
- 2007-06-22 CA CA2655570A patent/CA2655570C/en not_active Expired - Fee Related
- 2007-06-22 KR KR1020097001053A patent/KR101380128B1/ko not_active Expired - Fee Related
- 2007-06-22 DE DE602007010776T patent/DE602007010776D1/de active Active
- 2007-06-22 UA UAA200900468A patent/UA96156C2/ru unknown
- 2007-06-22 NZ NZ573454A patent/NZ573454A/en not_active IP Right Cessation
- 2007-06-22 EP EP07765584A patent/EP2034999B9/en active Active
- 2007-06-22 BR BRPI0713725-7A patent/BRPI0713725A2/pt not_active IP Right Cessation
- 2007-06-22 HR HR20110086T patent/HRP20110086T1/hr unknown
- 2007-06-22 DK DK07765584.3T patent/DK2034999T3/da active
- 2007-06-22 ES ES07765584T patent/ES2355611T3/es active Active
- 2007-06-22 JP JP2009517144A patent/JP5053372B2/ja not_active Expired - Fee Related
- 2007-06-22 MY MYPI20084785A patent/MY145985A/en unknown
- 2007-06-22 US US12/305,162 patent/US8034377B2/en not_active Expired - Fee Related
- 2007-06-22 RS RS20110091A patent/RS51629B/sr unknown
- 2007-06-22 PL PL07765584T patent/PL2034999T3/pl unknown
- 2007-06-22 GE GEAP200711074A patent/GEP20125464B/en unknown
- 2007-06-22 AU AU2007262958A patent/AU2007262958B2/en not_active Ceased
- 2007-06-22 CN CNA2007800228209A patent/CN101472590A/zh active Pending
- 2007-06-22 WO PCT/EP2007/056277 patent/WO2007147899A2/en not_active Ceased
- 2007-06-22 RU RU2008152248/04A patent/RU2451672C2/ru not_active IP Right Cessation
- 2007-06-22 AR ARP070102779A patent/AR061622A1/es not_active Application Discontinuation
- 2007-06-22 TW TW096122472A patent/TWI389888B/zh not_active IP Right Cessation
- 2007-06-23 SA SA07280345A patent/SA07280345B1/ar unknown
2008
- 2008-11-27 IL IL195562A patent/IL195562A/en active IP Right Grant
- 2008-11-27 HN HN2008001771A patent/HN2008001771A/es unknown
- 2008-12-12 CR CR10507A patent/CR10507A/es unknown
- 2008-12-19 TN TNP2008000527A patent/TNSN08527A1/en unknown
2009
- 2009-01-07 EC EC2009009039A patent/ECSP099039A/es unknown
- 2009-01-09 MA MA31561A patent/MA30584B1/fr unknown
- 2009-01-15 ZA ZA2009/00334A patent/ZA200900334B/en unknown
- 2009-01-21 NO NO20090334A patent/NO20090334L/no not_active Application Discontinuation
- 2009-01-22 CO CO09005510A patent/CO6150156A2/es unknown
2010
- 2010-10-13 CL CL2010001123A patent/CL2010001123A1/es unknown
2011
- 2011-06-13 US US13/159,022 patent/US8227479B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU2007262958B2 (en)	2011-10-27
JP2009544576A (ja)	2009-12-17
RS51629B (sr)	2011-08-31
WO2007147899B1 (en)	2008-05-02
KR101380128B1 (ko)	2014-04-11
AR061622A1 (es)	2008-09-10
IL195562A (en)	2012-06-28
SI2034999T1 (sl)	2011-02-28
GEP20125464B (en)	2012-04-10
SA07280345B1 (ar)	2011-01-15
NO20090334L (no)	2009-03-04
AU2007262958A1 (en)	2007-12-27
ES2355611T3 (es)	2011-03-29
ZA200900334B (en)	2009-12-30
CN101472590A (zh)	2009-07-01
US8227479B2 (en)	2012-07-24
TWI389888B (zh)	2013-03-21
NZ573454A (en)	2010-10-29
RU2008152248A (ru)	2010-07-27
CL2010001123A1 (es)	2011-03-25
WO2007147899A3 (en)	2008-03-13
US8034377B2 (en)	2011-10-11
CA2655570A1 (en)	2007-12-27
DE602007010776D1 (de)	2011-01-05
RU2451672C2 (ru)	2012-05-27
TW200811108A (en)	2008-03-01
MX2009000103A (es)	2009-01-23
BRPI0713725A2 (pt)	2012-10-30
CR10507A (es)	2009-02-05
FR2902659A1 (fr)	2007-12-28
CO6150156A2 (es)	2010-04-20
EP2034999B1 (en)	2010-11-24
IL195562A0 (en)	2009-09-01
MY145985A (en)	2012-05-31
PL2034999T3 (pl)	2011-05-31
MA30584B1 (fr)	2009-07-01
PT2034999E (pt)	2011-01-19
EP2034999B9 (en)	2011-03-09
EP2034999A2 (en)	2009-03-18
JP5053372B2 (ja)	2012-10-17
US20090312354A1 (en)	2009-12-17
TNSN08527A1 (en)	2010-04-14
US20110237613A1 (en)	2011-09-29
ATE489091T1 (de)	2010-12-15
UA96156C2 (ru)	2011-10-10
HN2008001771A (es)	2011-01-24
HRP20110086T1 (hr)	2011-03-31
ECSP099039A (es)	2009-02-27
CA2655570C (en)	2015-09-08
WO2007147899A2 (en)	2007-12-27
KR20090024794A (ko)	2009-03-09

Publication	Publication Date	Title
DK2034999T3 (da)	2011-01-24	DHA-estere og anvendelse deraf i behandlingen og forebyggelsen af cardiovaskulære sygdomme
SI2084151T1 (sl)	2013-10-30	Substituirani dihidropirazoloni za zdravljenje kardiovaskularnih in hematoloĹˇkih bolezni
LTPA2021506I1 (lt)	2021-05-10	Anti-P-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui
DK2259674T3 (da)	2014-08-04	Delta-4-desaturase og anvendelse heraf i fremstillingen af flerumættedefedtsyrer
DK2132317T3 (da)	2013-06-03	Delta-8-desaturaser og anvendelse heraf i fremstillingen af polyumættede fedtsyrer
EP2024476A4 (en)	2012-10-17	COMPOSITIONS CONTAINING LOW DEGREE POLYMERIZED POLYMERIZED SURFACTANTS AND METHODS OF USE THEREOF
NO20081842L (no)	2008-07-08	Fremgangsmåter og sammensetninger for anvendelse ved behandling av pasienter med autoantistoff-positive sykdommer
DK2185164T3 (da)	2017-11-13	Sammensætning og terapeutisk antitumorvaccine
IL197148A0 (en)	2011-08-01	Methods and compositions for the treatment of antibody mediated neuropathies
SI2046324T1 (sl)	2017-06-30	Zdravljenje in preventiva mukozitisa z derivati antocianidina
DK2235002T3 (da)	2013-03-11	4-pyridinonforbindelser og anvendelse heraf til behandling af cancer
PL2297106T3 (pl)	2015-01-30	Pochodne fenoksypirydynyloamidu i ich zastosowania w leczeniu chorób, w których pośredniczy pde4
EP2079526A4 (en)	2010-01-13	COMPOSITIONS AND ITS USES IN THE TREATMENT OF WOUNDS
HRP20190045T1 (hr)	2019-03-08	Metode i sastavi za liječenje upalne bolesti crijeva
IL201885A0 (en)	2011-08-01	Use of tp modulators for the treatment of cardiovascular disorders in aspirin sensitive and other populations
EP1951050A4 (en)	2011-04-27	THERAPEUTIC COMPOSITIONS AND METHOD
IL202351A0 (en)	2010-06-30	Substituted (oxazolidinon-5-yl-methyl)-2-thiophene-carboxamides and use thereof in the field of blood coagulation
NO20070892L (no)	2007-04-11	Sammensetninger av N-glykolylneuraminsyre og anvendelse derav ved behandling av forkjølelse.
EP2046368A4 (en)	2010-02-10	ANTI-COCAINE COMPOSITIONS AND TREATMENT
SI2341900T1 (sl)	2019-06-28	Medicinski proizvod in zdravljenje
DK2308497T3 (da)	2014-07-14	Farmaceutisk sammensætning omfattende glycosaminoglycaner og brug heraf ved behandling af kroniske mavesår
DK1984014T3 (da)	2014-09-15	Anvendelse af tpo-peptidforbindelser og farmaceutiske sammensætninger ved behandlingen af anæmi
FR2905270B1 (fr)	2010-03-26	Utilisation de sucres en c7 dans la prevention et le traitement des mycoses
PT2182954T (pt)	2019-02-06	Utilização de ácidos nor-biliares no tratamento de arteriosclerose
DOP2008000082A (es)	2009-04-30	Esteres de dha y su utilizacion en el tratamiento y la prevencion de enfermedades cardiovasculares.